
Please try another search
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor for the treatment of cervical cancer and other advanced solid tumors. It also develops other clinical stage assets, such as ATG-022, an antibody-drug conjugate which is in Phase II for the treatment of patients with advanced or metastatic gastric cancer; ATG-031, an anti-CD24 monoclonal antibody, which is in Phase I for the treatment of advanced solid tumors; ATG-037, an CD73 inhibitor that is in Phase I for the treatment of locally advanced or metastatic solid tumors; and ATG-101, a PD-L1/4-1BB bispecific antibody, which is I Phase I trial for the treatment of advanced/metastatic solid tumors and B-cell non Hodgkin lymphoma (B-NHL). In addition, the company’s pre-clinical stage assets consist of ATG-042, an PRMT5-MTA inhibitor; ATG-201 a CD19 x CD3 T cell engager; ATG-102, a LILRB4 x CD3 T cell engager; ATG-106, a CDH6 x CD3 T cell engager; ATG-107, a FLT3 x CD3 T cell engager; and ATG-110, a LY6G6D x CD3 T cell engager. Further, the company develops AnTenGager, an 2+1 T cell engager platform which enables conditional T cell activation with reduced risk of cytokine release syndrome; and engages in the trading activities. Antengene Corporation Limited was founded in 2017 and is based in Shanghai, China.
Name | Age | Since | Title |
---|---|---|---|
Jay Mei | 59 | 2018 | Founder, Chairman & CEO |
Donald Andrew Lung | 42 | 2020 | CFO & Executive Director |
Timothy M. Block | 69 | - | Member of Scientific Advisory Board |
Sheng Tang | 40 | 2020 | Independent Non-Executive Director |
Jing Qian | 48 | 2020 | Independent Non-Executive Director |
Shaji K. Kumar | - | - | Member of Scientific Advisory Board |
Joseph Camardo | 71 | - | Member of Scientific Advisory Board |
Robert Gale | - | - | Member of Scientific Advisory Board |
Wei-Li Zhao | - | - | Member of Scientific Advisory Board |
Ricky Johnstone | - | - | Member of Scientific Advisory Board |
Rafael Fonseca | 58 | 2023 | Independent Non-Executive Director |
Florence Houn | - | - | Member of the Scientific Advisory Board |
Yi-Long Wu | - | 2023 | Member of Scientific Advisory Board |
Jayesh Desai | - | 2023 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review